Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Non Operating Income (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Non Operating Income for 7 consecutive years, with -$136000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Non Operating Income fell 212.4% year-over-year to -$136000.0, compared with a TTM value of $82000.0 through Dec 2019, up 133.33%, and an annual FY2024 reading of $10.3 million, up 113.89% over the prior year.
  • Non Operating Income was -$136000.0 for Q4 2019 at Larimar Therapeutics, down from -$8000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $273000.0 in Q4 2017 and bottomed at -$254000.0 in Q1 2018.
  • Average Non Operating Income over 5 years is $34050.0, with a median of $66500.0 recorded in 2015.
  • The sharpest move saw Non Operating Income tumbled 468.25% in 2015, then surged 658.33% in 2017.
  • Year by year, Non Operating Income stood at $72000.0 in 2015, then crashed by 50.0% to $36000.0 in 2016, then soared by 658.33% to $273000.0 in 2017, then plummeted by 55.68% to $121000.0 in 2018, then plummeted by 212.4% to -$136000.0 in 2019.
  • Business Quant data shows Non Operating Income for LRMR at -$136000.0 in Q4 2019, -$8000.0 in Q3 2019, and $61000.0 in Q2 2019.